{"entity":{"id":"left-ventricular-dysfunction-on-her2-targeted-drugs","kind":"protocol","name":"Fall in heart pumping function (ejection fraction) on HER2-targeted drugs: scans and the hold, restart and stop rules by product","aka":["LVEF decline on trastuzumab","trastuzumab cardiotoxicity hold rules","left ventricular dysfunction on pertuzumab","ejection fraction fall on trastuzumab emtansine","ejection fraction fall on trastuzumab deruxtecan","HER2 therapy cardiac dysfunction","when to stop trastuzumab for the heart"],"tldr":"Trastuzumab and other HER2-targeted drugs can weaken the heart's pumping, so your team scans your heart before and during treatment. If the pumping measure (ejection fraction) falls past a set line, the drug is usually paused, the scan repeated in 3 to 4 weeks, and treatment restarted if it recovers. The lines differ by drug and country. Report new breathlessness or ankle swelling straight away.","summary":"Each HER2-targeted product's label sets its own rule for a fall in left ventricular ejection fraction (LVEF), and the rules differ between products and, for trastuzumab and lapatinib, between the US and EU texts. Trastuzumab, US label: LVEF before treatment, every 3 months during and at the end, and every 6 months for at least 2 years after adjuvant treatment; withhold for at least 4 weeks for an absolute fall of 16 points or more, or an LVEF below the institution's normal limit with a fall of 10 points or more; it may be resumed if within 4 to 8 weeks LVEF is back within normal limits and no more than 15 points below baseline; permanently discontinue for a fall lasting more than 8 weeks or more than 3 suspensions. Trastuzumab, EU SmPC: suspend for a fall of 10 points or more to below 50 per cent, repeat LVEF within about 3 weeks, and strongly consider discontinuation if it has not improved or symptomatic heart failure has developed, unless the benefit outweighs the risk; refer to a cardiologist. Pertuzumab with trastuzumab (US and EU, and the fixed-dose subcutaneous combination): withhold for at least 3 weeks in metastatic disease for LVEF below 40 per cent, or 40 to 45 per cent with a fall of 10 points or more; in early breast cancer for LVEF below 50 per cent with a fall of 10 points or more. Trastuzumab emtansine (US and EU): in metastatic disease withhold for LVEF below 40 per cent, or 40 to 45 per cent with a fall of 10 points or more; in early breast cancer for LVEF below 45 per cent, or 45 to 49 per cent with a fall of 10 points or more; repeat within about 3 weeks. Trastuzumab deruxtecan (US and EU): interrupt for LVEF 40 to 45 per cent with a fall of 10 to 20 points, for LVEF below 40 per cent or for a fall of more than 20 points; repeat within 3 weeks; permanently discontinue if the lower line is confirmed or for symptomatic heart failure. Zanidatamab (US and EU) and margetuximab (US) follow the 16-point and 10-point pattern of US trastuzumab, with 50 per cent as the limit (for margetuximab, where the institution has no normal limit of its own). Lapatinib: discontinue for a Grade 2 or greater LVEF decrease (US) or grade 3 or greater symptoms (EU), or LVEF below the lower limit of normal; it may be restarted at a reduced dose after at least 2 weeks if LVEF is normal and there are no symptoms.\n\nThe 2022 ESC guideline grades by severity instead. It recommends temporary interruption for moderate or severe symptomatic dysfunction (Class I, Level C, with heart failure therapy at Class I, Level B) and temporary interruption with heart failure therapy for a new asymptomatic LVEF below 40 per cent (Class I, Level C); says continuation should be considered with a new asymptomatic LVEF of 40 to 49 per cent with more frequent monitoring (Class IIa, Level B), with an ACE inhibitor or ARB and a beta-blocker (Class I, Level C); and says, in a footnote with no grade of its own, that resumption should be considered once LVEF is 40 per cent or more and symptoms have gone. ESMO (2020) is close to ESC. So a person with an asymptomatic LVEF in the 40s can fall on the hold side of a label and on the consider-continuing side of the guideline. Two small single-arm studies continued treatment on heart medicines: SAFE-HEaRt (31 patients with an LVEF of 40 to 49 per cent, supported by Genentech) and SCHOLAR (20 patients with an LVEF between 40 per cent and the lower limit of normal, or a fall of 15 points or more); in each, 1 in 10 had a cardiac event or a further marked fall. This page explains care; the treating team's own protocol comes first.","asOf":"2026-11-18","links":[],"tags":["protocol","cardio-oncology","her2"],"related":["cardio-oncology","cardio-oncology-risk-assessment-and-cardiac-surveillance","cardiomyopathy-surveillance-after-childhood-cancer","irae-myocarditis"],"cancers":[],"sections":["supportive-care"],"technologies":[],"targets":[],"drugs":["trastuzumab","pertuzumab","trastuzumab-emtansine","trastuzumab-deruxtecan","zanidatamab","margetuximab","lapatinib"],"companies":[],"institutions":["esmo","ema"],"pathways":[],"terms":["trastuzumab-cardiotoxicity","cardiotoxicity"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-lyon-eur-heart-j"],"journals":[],"dependsOn":[],"notes":[],"simple":"Some breast and stomach cancer medicines that target HER2 can make the heart pump less strongly. Heart scans check for this. If the scan result drops too far, the medicine is paused and the scan is repeated. If the result recovers, treatment can start again. Tell your team straight away if you get breathless or your ankles swell.","domain":"symptom-management","setting":{"who":["doctor","nurse","pharmacist","multidisciplinary-team","patient-or-carer"],"where":["outpatient-clinic","chemotherapy-day-unit","telephone-triage"]},"population":"Adults receiving trastuzumab (intravenous or subcutaneous), pertuzumab, trastuzumab emtansine, trastuzumab deruxtecan, zanidatamab, margetuximab or lapatinib. The pertuzumab, trastuzumab emtansine, trastuzumab deruxtecan, zanidatamab and margetuximab labels say those drugs have not been studied, or their safety not established, in people with a pre-treatment LVEF below 50 per cent (the combined pertuzumab and trastuzumab injection: below 55 per cent in early breast cancer). ESC says its monitoring recommendations for HER2-positive early breast cancer also apply to HER2-positive cancers outside the breast. Tucatinib and neratinib are not covered: their US labels hold no ejection fraction rule. Myocarditis from immune checkpoint inhibitors and anthracycline heart damage have their own pages.","trigger":"A routine heart scan during HER2-targeted treatment shows a fall in LVEF, or the person reports symptoms of heart failure.","steps":[{"action":"On trastuzumab, measure LVEF by echocardiogram or MUGA scan before the first dose, every 3 months during treatment and at its end, and after adjuvant treatment every 6 months for at least 2 years (US label)","why":"This is the schedule the US label recommends. The EU SmPC asks for the same 3-monthly checks and for checks every 6 months until 24 months after the last dose; for people who also had an anthracycline it recommends yearly checks up to 5 years from the last dose, or longer if LVEF keeps falling. The EU text says monitoring may help to identify patients who develop cardiac dysfunction.","source":"us-herceptin","quote":"Conduct thorough cardiac assessment, including history, physical examination, and determination of LVEF by echocardiogram or MUGA scan. The following schedule is recommended:"},{"action":"On the other HER2-targeted drugs, check LVEF before the first dose and at regular intervals during treatment; how often differs by product","why":"The trastuzumab emtansine labels give every three months as an example. The pertuzumab labels say about every 12 weeks, and once during treatment given before surgery. The margetuximab US label says every 3 months during treatment and at its end. The trastuzumab deruxtecan labels say at regular intervals as clinically indicated, and the zanidatamab labels say at regular intervals with no number. The lapatinib labels ask for LVEF before treatment and continued evaluation during it with no interval; its trials checked about every 8 weeks. ESC (2022) recommends an echocardiogram every 3 months on neoadjuvant or adjuvant HER2-targeted therapy (Class I, Level B).","source":"us-kadcyla","quote":"Assess LVEF prior to initiation of KADCYLA and at regular intervals (e.g. every three months) during treatment to ensure the LVEF is within the institution's normal limits."},{"action":"Trastuzumab, US label: withhold for at least 4 weeks if LVEF has fallen by 16 percentage points or more from the pre-treatment value, or is below the institution's normal limit with a fall of 10 points or more","why":"The US label gives the numbers without a stated reason. It asks for LVEF to be repeated at 4-week intervals while the drug is withheld, and says the safety of continuing or resuming trastuzumab in people whose heart function it has reduced has not been studied. The US label for trastuzumab given under the skin with hyaluronidase carries the same rule.","source":"us-herceptin","quote":"Withhold Herceptin for ≥ 16% absolute decrease in LVEF from pre-treatment values or an LVEF value below institutional limits of normal and ≥ 10% absolute decrease in LVEF from pretreatment values"},{"action":"Trastuzumab, US label: it may be restarted if, within 4 to 8 weeks, LVEF is back within normal limits and no more than 15 points below the pre-treatment value; stop for good if the fall lasts more than 8 weeks or dosing has been suspended for cardiomyopathy more than 3 times","why":"The label gives these limits without a stated reason. Its boxed warning adds: discontinue trastuzumab in people having adjuvant treatment, and withhold it in people with metastatic disease, for a clinically significant decrease in left ventricular function.","source":"us-herceptin","quote":"Herceptin may be resumed if, within 4–8 weeks, the LVEF returns to normal limits and the absolute decrease from baseline is ≤ 15%."},{"action":"Trastuzumab, EU SmPC: treatment should be suspended if LVEF has fallen by 10 points or more from baseline and to below 50 per cent, with a repeat LVEF within about 3 weeks","why":"The EU rule differs from the US one: it has no 16-point criterion, uses 50 per cent where the US label uses the institution's normal limit, and asks for the repeat scan at about 3 weeks where the US label says 4. The SmPC notes that the safety of continuing or resuming trastuzumab in people who develop cardiac dysfunction has not been prospectively studied.","source":"eu-herceptin","quote":"If left ventricular ejection fraction (LVEF) percentage drops ≥ 10 points from baseline AND to below 50 %, treatment should be suspended and a repeat LVEF assessment performed within approximately 3 weeks."},{"action":"Trastuzumab, EU SmPC: if LVEF has not improved or has fallen further at the repeat scan, or symptomatic heart failure has developed, strongly consider stopping unless the benefit for that person is judged to outweigh the risk, and refer to a cardiologist","why":"Unlike the US label, the EU text sets no number of weeks or of holds after which trastuzumab is stopped. It says symptomatic heart failure should be treated with standard heart failure medicines, and that most patients who developed heart failure or asymptomatic dysfunction in the pivotal trials improved on an ACE inhibitor or ARB and a beta-blocker. It also says patients who develop asymptomatic cardiac dysfunction may benefit from more frequent monitoring, for example every 6 to 8 weeks.","source":"eu-herceptin","quote":"If LVEF has not improved, or has declined further, or if symptomatic congestive heart failure (CHF) has developed, discontinuation of Herceptin should be strongly considered, unless the benefits for the individual patient are deemed to outweigh the risks. All such patients should be referred for assessment by a cardiologist and followed up."},{"action":"Pertuzumab with trastuzumab: withhold both for at least 3 weeks if, in metastatic breast cancer, LVEF falls below 40 per cent, or to 40 to 45 per cent with a fall of 10 points or more; in early breast cancer, if LVEF falls below 50 per cent with a fall of 10 points or more","why":"The US and EU pertuzumab texts give the same numbers. Treatment may be resumed in metastatic disease once LVEF is above 45 per cent, or is 40 to 45 per cent and less than 10 points below the pre-treatment value; in early breast cancer once it is 50 per cent or more, or less than 10 points below the pre-treatment value. The fixed-dose injection of pertuzumab and trastuzumab under the skin (Phesgo) carries the same thresholds in both regions. These numbers are not those of the trastuzumab labels, although the two drugs are given together.","source":"eu-perjeta","quote":"Perjeta and trastuzumab may be resumed if the LVEF has recovered to > 45%, or to 40-45% associated with a difference of < 10% points below pre-treatment values."},{"action":"Pertuzumab: if LVEF has not improved, or has fallen further, at the next assessment, consider stopping pertuzumab and trastuzumab for good (US label); the EU SmPC says stopping should be strongly considered, and the US label of the combined injection says to stop for good","why":"Three texts for the same medicines use three strengths. US Perjeta: consider permanent discontinuation. EU Perjeta and EU Phesgo: discontinuation should be strongly considered unless the benefits for the individual patient are deemed to outweigh the risks. US Phesgo: permanently discontinue if, after a repeat assessment within approximately 3 weeks, LVEF has not improved, has declined further, or the patient is symptomatic. The boxed warning of the US Perjeta label is firmer than its body text: discontinue pertuzumab for a confirmed clinically significant decrease in left ventricular function. The labels do not explain the difference.","source":"us-perjeta","quote":"If the LVEF declines and has not improved, or has declined further at the subsequent assessment, consider permanent discontinuation of PERJETA and trastuzumab"},{"action":"Trastuzumab emtansine in metastatic breast cancer: withhold if LVEF is below 40 per cent, or is 40 to 45 per cent with a fall of 10 points or more, and repeat the LVEF within about 3 weeks; stop for good if it has not improved or has fallen further. In early breast cancer the lines are below 45 per cent, and 45 to 49 per cent with a fall of 10 points or more","why":"The US and EU texts carry the same tables. With a smaller fall (less than 10 points) in the same band, treatment continues and the scan is repeated within 3 weeks. Both say to discontinue for symptomatic heart failure; in early breast cancer that row also covers Grade 3 to 4 left ventricular systolic dysfunction or heart failure, and Grade 2 heart failure with LVEF below 45 per cent. The US label reports, from a retrospective observational study, that 22 per cent (7 of 32) of people with metastatic breast cancer who started with an LVEF of 40 to 49 per cent developed heart failure or a fall in LVEF of more than 10 per cent.","source":"us-kadcyla","quote":"For patients with MBC, if, at routine monitoring, LVEF is < 40%, or is 40% to 45% with a 10% or greater absolute decrease below the pretreatment value, withhold KADCYLA and repeat LVEF assessment within approximately 3 weeks. Permanently discontinue KADCYLA if the LVEF has not improved or has declined further."},{"action":"Trastuzumab deruxtecan: interrupt if LVEF is 40 to 45 per cent with a fall of 10 to 20 points from baseline, or is below 40 per cent, or has fallen by more than 20 points; repeat the LVEF within 3 weeks; stop for good if LVEF below 40 per cent or a fall of more than 20 points is confirmed, or if symptomatic heart failure develops","why":"The US and EU tables are the same. With LVEF above 45 per cent and a fall of 10 to 20 points, or LVEF of 40 to 45 per cent and a fall of less than 10 points, treatment continues, with a repeat scan within 3 weeks in the second case. After an interruption for LVEF of 40 to 45 per cent with a fall of 10 to 20 points, treatment resumes at the same dose if LVEF recovers to within 10 per cent from baseline, in the label's words, and is stopped for good if it does not. Unlike the trastuzumab labels, neither text sets a scan interval: both say at regular intervals as clinically indicated.","source":"us-enhertu","quote":"Permanently discontinue ENHERTU if LVEF of less than 40% or absolute decrease from baseline of greater than 20% is confirmed. Permanently discontinue ENHERTU in patients with symptomatic congestive heart failure (CHF)"},{"action":"Zanidatamab: withhold for at least 4 weeks if LVEF has fallen by 16 points or more, or is below 50 per cent with a fall of 10 points or more; repeat the LVEF within 4 weeks; restart within 4 to 8 weeks if LVEF is back within normal limits and no more than 15 points below baseline; stop for good if it has not recovered to within 15 points of baseline","why":"The US and EU tables match on these numbers. The US table has a row the EU table does not: stop for good for confirmed symptomatic congestive heart failure. The EU SmPC says that if LVEF declines and has not improved, or has declined further at the next assessment, zanidatamab should be discontinued as its table recommends. The US label says the safety of zanidatamab has not been established in people whose baseline ejection fraction is below 50 per cent.","source":"us-ziihera","quote":"Resume ZIIHERA treatment within 4 to 8 weeks if LVEF returns to normal limits and the absolute decrease is ≤ 15% points from baseline."},{"action":"Margetuximab (US label only): withhold for at least 4 weeks for a fall in LVEF of 16 points or more, or an LVEF below the institution's normal limit (or 50 per cent if it has none) with a fall of 10 points or more; it may be restarted if, within 8 weeks, LVEF is back within normal limits and no more than 15 points below the pre-treatment value; stop for good if the fall lasts more than 8 weeks or dosing is interrupted more than 3 times","why":"The US label asks for a baseline LVEF within 4 weeks before the first dose, LVEF every 3 months during treatment and at its end, and a repeat at 4-week intervals while the drug is withheld. It gives no reason for the numbers, and says margetuximab has not been studied in people with a pre-treatment LVEF below 50 per cent. No EU product information for margetuximab was found.","source":"us-margenza","quote":"MARGENZA dosing may be resumed if, within 8 weeks, LVEF returns to normal limits and absolute decrease from baseline is ≤ 15%."},{"action":"Lapatinib: the US label says it should be discontinued if the LVEF decrease is Grade 2 or greater or LVEF drops below the institution's lower limit of normal; the EU SmPC, for symptoms of decreased LVEF of grade 3 or greater or LVEF below the lower limit of normal. It may be restarted at a reduced dose after at least 2 weeks if LVEF is normal again and there are no symptoms","why":"The two texts differ on the grade: the US label names a decreased LVEF that is Grade 2 or greater on NCI CTCAE version 3.0, the EU SmPC symptoms associated with decreased LVEF that are grade 3 or greater. The reduced restart doses are 1,000 mg a day with capecitabine and 1,250 mg a day with letrozole (US) or an aromatase inhibitor (EU); the EU text adds 750 mg a day with trastuzumab. The US label says most LVEF decreases in trials (greater than 57 per cent) occurred within the first 12 weeks of treatment.","source":"us-tykerb","quote":"TYKERB should be discontinued in patients with a decreased left ventricular ejection fraction (LVEF) that is Grade 2 or greater by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v3.0), and in patients with an LVEF that drops below the institution’s lower limit of normal (LLN)"},{"action":"Under the ESC guideline, interrupt HER2-targeted therapy temporarily and start heart failure treatment when LVEF falls below 40 per cent without symptoms, or when moderate or severe symptomatic heart failure develops; decide on restarting with a multidisciplinary team","why":"ESC grades the problem by severity instead of by a fall from baseline alone: severe dysfunction without symptoms is a new LVEF below 40 per cent. For moderate or severe symptomatic dysfunction it recommends the same temporary interruption, with the decision to restart made by a multidisciplinary team after left ventricular function has improved and symptoms have resolved (Class I, Level C), and heart failure therapy (Class I, Level B). For mild symptoms it recommends heart failure therapy and a multidisciplinary decision on continuing or interrupting (Class I, Level C). ESMO (2020) says trastuzumab or any HER2-based therapy should be withheld until cardiac status has stabilised in a patient with signs and symptoms of heart failure, or without symptoms and an LVEF below 40 per cent [I, A].","source":"esc-2022","quote":"Temporary interruption of HER2-targeted therapy and initiation of HF therapy is recommended in patients who develop asymptomatic severe CTRCD.","grade":"Class I, Level C"},{"action":"With no symptoms and an LVEF of 40 to 49 per cent, consider continuing HER2-targeted therapy with more frequent heart monitoring, and start an ACE inhibitor or ARB and a beta-blocker (ESC); several labels would withhold treatment in this range","why":"ESC recommends the ACE inhibitor or ARB and beta-blocker in this group (Class I, Level C). Its text is firmer than its table: the text says treatment should be continued, the table that continuation should be considered. This is where guideline and labels part. The EU trastuzumab SmPC suspends treatment for a fall of 10 points or more to below 50 per cent; the pertuzumab labels withhold in early breast cancer for the same fall; the trastuzumab emtansine labels withhold in early breast cancer below 45 per cent, or at 45 to 49 per cent with a fall of 10 points or more. ESMO (2020) says it is possible that trastuzumab may be continued with mild asymptomatic reductions in LVEF [III, A]. With LVEF still 50 per cent or more and only a significant fall in strain or a rise in troponin or natriuretic peptide, ESC recommends continuing with more frequent monitoring (Class I, Level C).","source":"esc-2022","quote":"Continuation of HER2-targeted therapy should be considered in patients who develop asymptomatic moderate (LVEF 40–49%) CTRCD","grade":"Class IIa, Level B"},{"action":"After an interruption, consider restarting HER2-targeted therapy once LVEF has recovered to 40 per cent or more and symptoms have gone, on heart failure treatment, with an echocardiogram and cardiac blood tests every two cycles for the first four cycles (ESC)","why":"This is a footnote to ESC's Class I, Level C recommendations and carries no grade of its own; the text adds that recovery to 50 per cent or more is ideal. It is looser than the labels: US trastuzumab asks for LVEF back within normal limits and no more than 15 points below baseline within 4 to 8 weeks, and pertuzumab in early breast cancer for 50 per cent or more, or less than 10 points below baseline. ESMO (2020) says resumption should be considered when LVEF is 40 per cent or more and/or heart failure symptoms have resolved, supported by continued heart failure treatment and periodic biomarker and LVEF checks [III, B]. Where symptoms do not resolve or LVEF stays below 40 per cent, both say resumption may be considered if no alternative treatment exists (ESMO [IV, C]; ESC in a figure footnote).","source":"esc-2022","quote":"For patients where HER2-targeted therapy has been interrupted and who have recovered LVEF ≥ 40% and are now asymptomatic, resumption of HER2-targeted therapy should be considered"},{"action":"Advise the person to contact a health professional immediately about new or worsening breathlessness, cough, swelling of the ankles or legs, swelling of the face, palpitations, sudden weight gain, dizziness or loss of consciousness","why":"The US trastuzumab label asks prescribers to give this advice, with weight gain of more than 5 pounds in 24 hours as its figure. The US patient guides for trastuzumab deruxtecan and zanidatamab and the EU leaflets for trastuzumab, pertuzumab and trastuzumab emtansine give similar lists and ask patients to tell their doctor or nurse right away, straight away or immediately. ESMO says early recognition of the signs and symptoms of heart failure is vital to allow early treatment.","source":"us-herceptin","quote":"Advise patients to contact a health care professional immediately for any of the following: new onset or worsening shortness of breath, cough, swelling of the ankles/legs, swelling of the face, palpitations, weight gain of more than 5 pounds in 24 hours, dizziness or loss of consciousness"}],"bestInClass":{"statement":"There are two kinds of rule and they do not agree. The dose rule for each product is its own label, and a label is the right source for a hold, restart or stop rule. The labels differ from each other: US trastuzumab, zanidatamab and US margetuximab act on a fall of 16 points, or 10 points to below a normal limit, hold for at least 4 weeks and allow up to 8 weeks for recovery; EU trastuzumab acts on a fall of 10 points or more to below 50 per cent and repeats the scan at about 3 weeks; pertuzumab and trastuzumab emtansine use fixed bands with a hold or repeat scan at about 3 weeks (in metastatic disease, both: below 40 per cent, or 40 to 45 per cent with a fall of 10 points or more; in early breast cancer, pertuzumab: below 50 per cent with a fall of 10 points or more; trastuzumab emtansine: below 45 per cent, or 45 to 49 per cent with a fall of 10 points or more); trastuzumab deruxtecan interrupts only at 40 to 45 per cent with a fall of 10 to 20 points, below 40 per cent or after a fall of more than 20 points; lapatinib uses a CTCAE grade, and the US and EU texts name different grades. The management guideline is the 2022 ESC cardio-oncology guideline, the most recent graded text (no later edition or focused update was found on 18 November 2026): it grades by severity, recommends temporary interruption for symptomatic moderate or severe dysfunction or a new asymptomatic LVEF below 40 per cent (Class I, Level C), leaves the choice between continuing and interrupting in mild symptomatic dysfunction to a multidisciplinary decision (Class I, Level C), and says continuation should be considered at 40 to 49 per cent without symptoms (Class IIa, Level B) with an ACE inhibitor or ARB and a beta-blocker (Class I, Level C). ESMO (2020) takes a similar line with its own grades: withhold with heart failure or LVEF below 40 per cent [I, A]; trastuzumab may possibly be continued with mild asymptomatic reductions [III, A]. ESC grades its continue-at-40-to-49 advice Level B and ESMO grades its own Level III (prospective cohort studies). The prospective studies read for this page are two single-arm studies of 31 and 20 patients; SCHOLAR's authors wrote in 2019 that it was one of only two trials to have tested continuing trastuzumab despite cardiotoxicity prospectively. No randomised comparison of continuing against holding was found in the sources read. Both positions are shown here; which applies to a given person is for the treating team and, as ESC recommends, a multidisciplinary discussion.","sources":["us-herceptin","eu-herceptin","us-perjeta","eu-perjeta","us-kadcyla","us-enhertu","us-ziihera","us-margenza","us-tykerb","esc-2022","esmo-2020","safe-heart-2019","scholar-2019"]},"variants":[{"name":"Trastuzumab: US label and EU SmPC side by side","differs":"US: withhold for at least 4 weeks for a fall of 16 points or more, or an LVEF below the institution's normal limit with a fall of 10 points or more; repeat LVEF every 4 weeks; resume if recovered within 4 to 8 weeks; permanently discontinue for a fall lasting more than 8 weeks or more than 3 suspensions. EU: suspend for a fall of 10 points or more to below 50 per cent; repeat within about 3 weeks; strongly consider discontinuation if not improved or symptomatic, unless benefit outweighs risk; cardiologist referral. Follow-up after adjuvant treatment: US every 6 months for at least 2 years; EU every 6 months until 24 months, then yearly up to 5 years after an anthracycline.","evidence":"Regulatory texts for the same medicine from the same company; neither states the evidence for its thresholds. Both say the safety of continuing or resuming trastuzumab after cardiac dysfunction has not been studied (EU: not prospectively studied).","sources":["us-herceptin","eu-herceptin"]},{"name":"Fixed-dose pertuzumab and trastuzumab under the skin (Phesgo)","differs":"Same LVEF thresholds and 3-week hold as intravenous pertuzumab in both regions. The US label is firmer on stopping than US Perjeta: permanently discontinue if, after a repeat assessment within approximately 3 weeks, LVEF has not improved, has declined further, or the patient is symptomatic. It also asks for LVEF every 6 months for at least 2 years after adjuvant treatment. The EU SmPC says discontinuation should be strongly considered unless benefits outweigh risks.","evidence":"Regulatory labels. The US label reports from the FeDeriCa trial heart failure (NYHA class III or IV) with an LVEF fall of 10 points or more to below 50 per cent in 0.8 per cent of the Phesgo arm.","sources":["us-phesgo","eu-phesgo"]},{"name":"Continuing HER2-targeted therapy at LVEF 40 to 49 per cent on heart medicines: SAFE-HEaRt (funded by Genentech)","differs":"Patients with stage I to IV HER2-positive breast cancer and an LVEF of 40 to 49 per cent without heart failure symptoms were given trastuzumab, trastuzumab with pertuzumab, or trastuzumab emtansine without interruption, with a beta-blocker and an ACE inhibitor or ARB unless contraindicated, cardiology visits and serial echocardiograms.","evidence":"A single-arm pilot at three US centres: 31 enrolled, 30 evaluable; 27 (90 per cent) completed planned treatment; 2 had a cardiac event and 1 an asymptomatic fall in LVEF to 35 per cent or less. At a median follow-up of 42 months, mean LVEF in the 23 patients with data was 52.1 per cent against 44.9 per cent at baseline; one more patient had developed symptomatic heart failure, and there were no cardiac deaths. The authors name the small sample, the lack of randomisation and the mixed population as limits. Supported by Genentech (Roche), which supplied the study drugs, with NCI and foundation grants.","sources":["safe-heart-2019","safe-heart-2021"]},{"name":"Continuing trastuzumab despite mild cardiotoxicity: SCHOLAR","differs":"Patients on adjuvant trastuzumab for stage I to III breast cancer with an LVEF between 40 per cent and the lower limit of normal, or a fall of 15 points or more from baseline, continued trastuzumab with an ACE inhibitor and/or beta-blocker in a cardio-oncology clinic, with serial echocardiograms for 1 year.","evidence":"A phase I single-arm trial at one Canadian centre: 20 participants; 18 (90 per cent) received all planned doses; 2 (10 per cent) developed heart failure with LVEF below 40 per cent, which improved to nearly normal after trastuzumab was permanently stopped; no deaths. The authors conclude that about 10 per cent of patients may develop moderate to severe heart failure with this approach, and name the 1-year follow-up, single centre and small sample as limits. Supported by Hamilton Health Sciences; one author reports advisory-board honoraria from Roche.","sources":["scholar-2019"]},{"name":"ESMO consensus recommendations (2020)","differs":"For an asymptomatic fall of 10 per cent or more from baseline, or a drop to 40 to below 50 per cent, on trastuzumab: cardiology consultation, consider cardioprotective treatment, consider monthly biomarkers, and if trastuzumab is stopped repeat LVEF within 3 to 6 weeks and resume if LVEF has normalised to above 50 per cent. With heart failure or LVEF below 40 per cent: withhold until cardiac status has stabilised and discuss risks and benefits of continuing with the multidisciplinary team and the patient.","evidence":"ESMO grades these [III, A] and [I, A]. Its 3 to 6 week repeat and its restart line of above 50 per cent are not the same as ESC's (restart should be considered from 40 per cent). No external funding; several authors declare advisory roles with manufacturers of HER2-targeted drugs.","sources":["esmo-2020"]}],"grades":[{"claim":"Trastuzumab, US: when to stop for good","grade":"Not graded (regulatory label)","source":"us-herceptin","quote":"Permanently discontinue Herceptin for a persistent (> 8 weeks) LVEF decline or for suspension of Herceptin dosing on more than 3 occasions for cardiomyopathy."},{"claim":"Trastuzumab, US: scans while the drug is withheld","grade":"Not graded (regulatory label)","source":"us-herceptin","quote":"Repeat LVEF measurement at 4 week intervals if Herceptin is withheld for significant left ventricular cardiac dysfunction"},{"claim":"Trastuzumab, EU: scan schedule during and after treatment","grade":"Not graded (regulatory label)","source":"eu-herceptin","quote":"Cardiac assessments, as performed at baseline, should be repeated every 3 months during treatment and every 6 months following discontinuation of treatment until 24 months from the last administration of Herceptin."},{"claim":"Pertuzumab, EU: restart in early breast cancer","grade":"Not graded (regulatory label)","source":"eu-perjeta","quote":"Perjeta and trastuzumab may be resumed if the LVEF has recovered to ≥50% or to a difference of < 10% points below pre-treatment values."},{"claim":"Pertuzumab, EU: when LVEF has not recovered","grade":"Not graded (regulatory label)","source":"eu-perjeta","quote":"If the LVEF has declined as indicated in section 4.2 and has not improved, or has declined further at the subsequent assessment, discontinuation of Perjeta and trastuzumab should be strongly considered, unless the benefits for the individual patient are deemed to outweigh the risks."},{"claim":"Fixed-dose combination, US: when LVEF has not recovered","grade":"Not graded (regulatory label)","source":"us-phesgo","quote":"If after a repeat assessment within approximately 3 weeks, the LVEF has not improved, has declined further, and/or the patient is symptomatic, permanently discontinue PHESGO"},{"claim":"Fixed-dose combination, EU: hold in early breast cancer","grade":"Not graded (regulatory label)","source":"eu-phesgo","quote":"Phesgo should be withheld for at least 3 weeks for a drop in LVEF to less than 50 % associated with a fall of ≥ 10 % points below pre-treatment values."},{"claim":"Trastuzumab emtansine, US: early breast cancer","grade":"Not graded (regulatory label)","source":"us-kadcyla","quote":"For patients with EBC, if, at routine monitoring, LVEF is < 45%, or is 45% to 49% with a 10% or greater absolute decrease below the pretreatment value, withhold KADCYLA and repeat LVEF assessment within approximately 3 weeks. Permanently discontinue KADCYLA if the LVEF has not improved or has declined further"},{"claim":"Trastuzumab emtansine, EU: scans","grade":"Not graded (regulatory label)","source":"eu-kadcyla","quote":"Standard cardiac function testing (echocardiogram or multigated acquisition (MUGA) scanning) should be performed prior to initiation of treatment and also at regular intervals (e.g. every three months) during treatment."},{"claim":"Trastuzumab deruxtecan, EU: when to stop for good","grade":"Not graded (regulatory label)","source":"eu-enhertu","quote":"Enhertu should be permanently discontinued if LVEF of less than 40% or absolute decrease from baseline of greater than 20% is confirmed."},{"claim":"Zanidatamab, EU: when LVEF has not recovered","grade":"Not graded (regulatory label)","source":"eu-ziihera","quote":"If the LVEF declines and has not improved, or has declined further at the subsequent assessment, Ziihera should be discontinued as recommended in Table 1 (see section 4.2)."},{"claim":"Margetuximab, US: when to stop for good","grade":"Not graded (regulatory label)","source":"us-margenza","quote":"Permanently discontinue MARGENZA if LVEF decline persists for greater than 8 weeks, or if dosing is interrupted on greater than 3 occasions for LVEF decline."},{"claim":"Lapatinib, EU: when to discontinue","grade":"Not graded (regulatory label)","source":"eu-tyverb","quote":"Tyverb should be discontinued in patients with symptoms associated with decreased left ventricular ejection fraction (LVEF) that are National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) grade 3 or greater or if their LVEF drops below the institutions lower limit of normal (see section 4.4)."},{"claim":"ESC: moderate or severe symptomatic dysfunction","grade":"Class I, Level C","source":"esc-2022","quote":"Temporary interruption of HER2-targeted treatment is recommended in patients who develop moderate or severe symptomatic CTRCD and the decision to restart should be based on a multidisciplinary approach after improvement of LV function and symptoms resolved."},{"claim":"ESC: mild symptomatic dysfunction","grade":"Class I, Level C","source":"esc-2022","quote":"In patients who develop mild symptomatic CTRCD, HF therapy and a multidisciplinary approach regarding the decision to continue vs. interrupt HER2-targeted therapy are recommended."},{"claim":"ESC: restarting after severe asymptomatic dysfunction","grade":"Class I, Level C","source":"esc-2022","quote":"A multidisciplinary approach regarding the decision to restart HER2-targeted treatment is recommended in patients with severe asymptomatic CTRCD."},{"claim":"ESC, in its text: asymptomatic LVEF of 40 to 49 per cent","grade":"Guideline text; the matching table rows are Class IIa, Level B (continuation) and Class I, Level C (ACE inhibitor or ARB and beta-blocker)","source":"esc-2022","quote":"In patients with asymptomatic moderate CTRCD (LVEF 40–49%), HER2-targeted treatment should be continued, and cardioprotective therapy (ACE-I/ARB and betablockers) is recommended with frequent cardiac monitoring."},{"claim":"ESMO: heart failure, or LVEF below 40 per cent without symptoms","grade":"[I, A]","source":"esmo-2020","quote":"In addition, trastuzumab (or any HER2-based therapy) should be withheld until the cardiac status has stabilised. A discussion regarding the risks and benefits of continuation should be held with the multidisciplinary team and the patient [I, A]."},{"claim":"ESMO: mild asymptomatic reductions (the grade is printed once, at the end of Recommendation 5.2, after this sentence)","grade":"[III, A]","source":"esmo-2020","quote":"It is possible that trastuzumab therapy may be continued with mild asymptomatic reductions in LVEF [III, A]."},{"claim":"ESMO: restarting after an interruption","grade":"[III, B]","source":"esmo-2020","quote":"For a patient in whom trastuzumab therapy (or any HER2-targeted molecular therapy) has been interrupted, whose LVEF is ≥40% and/or whose signs and symptoms of HF have resolved, resumption of trastuzumab therapy should be considered, supported by:"},{"claim":"ESMO: restarting when the heart has not recovered","grade":"[IV, C]","source":"esmo-2020","quote":"For a patient in whom trastuzumab therapy (or any HER2-targeted molecular therapy) has been interrupted, whose signs and symptoms of HF do not resolve and/or LVEF remains <40%, resumption of trastuzumab therapy may be considered if no alternative therapeutic option exists."}],"sources":[{"key":"us-herceptin","label":"Herceptin (trastuzumab) for injection: US prescribing information, SPL effective 29 May 2026","publisher":"Genentech, on DailyMed (US National Library of Medicine)","year":2026,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=492dbdb2-077e-4064-bff3-372d6af0a7a2","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-18"},{"key":"eu-herceptin","label":"Herceptin (trastuzumab): EU summary of product characteristics and package leaflet, EMA file dated 28 October 2025","publisher":"Roche, on the European Medicines Agency website","year":2025,"url":"https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-18"},{"key":"us-perjeta","label":"Perjeta (pertuzumab) injection: US prescribing information, SPL effective 30 April 2026","publisher":"Genentech, on DailyMed (US National Library of Medicine)","year":2026,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17f85d17-ab71-4f5b-9fe3-0b8c822f69ff","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-18"},{"key":"eu-perjeta","label":"Perjeta (pertuzumab): EU summary of product characteristics and package leaflet, EMA file dated 29 January 2026","publisher":"Roche, on the European Medicines Agency website","year":2026,"url":"https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-18"},{"key":"us-phesgo","label":"Phesgo (pertuzumab, trastuzumab and hyaluronidase) injection: US prescribing information, SPL effective 23 September 2026","publisher":"Genentech, on DailyMed (US National Library of Medicine)","year":2026,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27dd5e6b-72cd-458d-a015-cf4dab5800da","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-18"},{"key":"eu-phesgo","label":"Phesgo (pertuzumab and trastuzumab): EU summary of product characteristics and package leaflet, EMA file dated 8 September 2026","publisher":"Roche, on the European Medicines Agency website","year":2026,"url":"https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-18"},{"key":"us-kadcyla","label":"Kadcyla (ado-trastuzumab emtansine) for injection: US prescribing information, SPL effective 1 April 2026","publisher":"Genentech, on DailyMed (US National Library of Medicine)","year":2026,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23f3c1f4-0fc8-4804-a9e3-04cf25dd302e","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-18"},{"key":"eu-kadcyla","label":"Kadcyla (trastuzumab emtansine): EU summary of product characteristics and package leaflet, EMA file dated 20 April 2026","publisher":"Roche, on the European Medicines Agency website","year":2026,"url":"https://www.ema.europa.eu/en/documents/product-information/kadcyla-epar-product-information_en.pdf","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-18"},{"key":"us-enhertu","label":"Enhertu (fam-trastuzumab deruxtecan-nxki) for injection: US prescribing information and Medication Guide, revised 05/2026","publisher":"Daiichi Sankyo, on DailyMed (US National Library of Medicine)","year":2026,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e67e73e-ddf4-4e4d-8b50-09d7514910b6","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-18"},{"key":"eu-enhertu","label":"Enhertu (trastuzumab deruxtecan): EU summary of product characteristics and package leaflet, EMA file dated 20 August 2026","publisher":"Daiichi Sankyo, on the European Medicines Agency website","year":2026,"url":"https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-18"},{"key":"us-ziihera","label":"Ziihera (zanidatamab-hrii) for injection: US prescribing information and Medication Guide, revised 08/2026","publisher":"Jazz Pharmaceuticals, on DailyMed (US National Library of Medicine)","year":2026,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae5d9425-fae5-4541-a158-150998343348","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-18"},{"key":"eu-ziihera","label":"Ziihera (zanidatamab): EU summary of product characteristics and package leaflet, EMA file dated 14 June 2026","publisher":"Jazz Pharmaceuticals, on the European Medicines Agency website","year":2026,"url":"https://www.ema.europa.eu/en/documents/product-information/ziihera-epar-product-information_en.pdf","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-18"},{"key":"us-margenza","label":"Margenza (margetuximab-cmkb) injection: US prescribing information, SPL effective 11 February 2025","publisher":"TerSera Therapeutics, on DailyMed (US National Library of Medicine)","year":2025,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6a6d50c7-06ea-479c-83cc-f197a9e428c9","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-18"},{"key":"us-tykerb","label":"Tykerb (lapatinib) tablets: US prescribing information and patient information, revised December 2024","publisher":"Novartis, on DailyMed (US National Library of Medicine)","year":2024,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eee37f88-ec6a-4c30-b8aa-e2c71f93088c","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-18"},{"key":"eu-tyverb","label":"Tyverb (lapatinib): EU summary of product characteristics and package leaflet, EMA file dated 4 September 2025","publisher":"Novartis, on the European Medicines Agency website","year":2025,"url":"https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-18"},{"key":"esc-2022","label":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","publisher":"ESC, European Heart Journal; read from the publisher's PDF in an open university repository","year":2022,"url":"https://doi.org/10.1093/eurheartj/ehac244","doi":"10.1093/eurheartj/ehac244","gradingScheme":"Class of recommendation I (recommended), IIa (should be considered), IIb (may be considered), III (not recommended); level of evidence A (multiple randomised trials or meta-analyses), B (one randomised trial or large non-randomised studies), C (expert consensus, small studies, retrospective studies or registries).","read":"full-text","accessed":"2026-11-18"},{"key":"esmo-2020","label":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","publisher":"ESMO, Annals of Oncology (no external funding; production costs covered by ESMO)","year":2020,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8019325/","doi":"10.1016/j.annonc.2019.10.023","gradingScheme":"Level of evidence I (large randomised trial or meta-analysis) to V (no control group, case reports, expert opinion); grade of recommendation A (strongly recommended) to E (never recommended), adapted from the Infectious Diseases Society of America system; printed as [level, grade].","read":"full-text","accessed":"2026-11-18"},{"key":"safe-heart-2019","label":"Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study (supported by Genentech, which supplied the study drugs)","publisher":"Lynce et al., Breast Cancer Research and Treatment","year":2019,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6534513/","doi":"10.1007/s10549-019-05191-2","gradingScheme":"Single-arm pilot study; not graded.","read":"full-text","accessed":"2026-11-18"},{"key":"safe-heart-2021","label":"Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function (supported by Genentech, which supplied the study drugs)","publisher":"Khoury et al., Breast Cancer Research and Treatment","year":2021,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8207895/","doi":"10.1007/s10549-020-06053-y","gradingScheme":"Follow-up of a single-arm pilot study; not graded.","read":"full-text","accessed":"2026-11-18"},{"key":"scholar-2019","label":"Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity: A Phase I Trial (SCHOLAR)","publisher":"Leong et al., JACC: CardioOncology (supported by Hamilton Health Sciences)","year":2019,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8352338/","doi":"10.1016/j.jaccao.2019.06.004","gradingScheme":"Single-arm phase I trial; not graded.","read":"full-text","accessed":"2026-11-18"},{"key":"asco-2017","label":"Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline","publisher":"ASCO, Journal of Clinical Oncology","year":2017,"url":"https://europepmc.org/abstract/MED/27918725","doi":"10.1200/JCO.2016.70.5400","read":"abstract","accessed":"2026-11-18"}],"upgrades":[],"gaps":["No source read reports a trial comparing the labels' hold rules with one another or with the ESC approach, and no label states the evidence for its thresholds. The prospective studies read on continuing treatment with an asymptomatic LVEF of 40 to 49 per cent are two single-arm studies of 31 and 20 patients, one of them supported by the manufacturer; the other studies ESC and ESMO cite for this advice were not read.","Several labels say their drug has not been studied in people who start with an LVEF below 50 per cent (the combined pertuzumab and trastuzumab injection: below 55 per cent in early breast cancer); how the hold rules apply to them is not settled by any source read.","The labels word their thresholds in different units ('% absolute decrease', '%-points', '10% from baseline'), and the trastuzumab deruxtecan label's 'within 10% from baseline' is given here in its own words because it does not say absolute or relative.","No trastuzumab biosimilar label was read; whether each carries the same cardiac text as Herceptin was not checked. The US label for subcutaneous trastuzumab with hyaluronidase (Herceptin Hylecta) was read and carries the same rule as intravenous Herceptin.","No EU product information for margetuximab was found: the EMA addresses for it returned 404 on 18 November 2026. Its rule on this page is the US label's only.","Tucatinib and neratinib are not covered. Their US labels were read and hold no rule on ejection fraction; the EU neratinib SmPC asks only for cardiac monitoring, including LVEF, as clinically indicated in people with known cardiac risk factors.","The EMA product-information files print no date of revision; the dates given are those of the PDF files. The US labels for trastuzumab, pertuzumab, Phesgo, trastuzumab emtansine and margetuximab print no revision line in the text read, so the SPL effective date is given.","The 2022 ESC guideline was read from the published PDF held in an open university repository, re-used from an earlier round; the publisher's page refuses a script. Its Figure 26 (the management flowchart) was read only through its legend. Its two 2023 errata (10.1093/eurheartj/ehad196 and 10.1093/ehjci/jead080) could not be read: on 18 November 2026 the publisher's site refused a script and neither is in PubMed Central, so whether they touch the recommendations quoted here is not known. The PDF read was generated on 20 March 2023, three days before the first erratum was published. ESC's recommendations name HER2-targeted therapy as a class and do not separate antibodies, conjugates and kinase inhibitors.","The ASCO 2017 guideline was read only as an abstract, which says nothing on holding or restarting HER2-targeted therapy; its full recommendations are not on this page. A 2025 Heart Failure Association consensus statement on preventing cancer therapy-related cardiac dysfunction (10.1002/ejhf.3753) exists and could not be read: on 18 November 2026 the publisher's site refused a script and no open copy was found in PubMed Central.","Which heart failure medicines to use, their doses, and the role of strain imaging and blood biomarkers in deciding to hold are covered only as far as the quoted recommendations go.","The US labels for trastuzumab, pertuzumab, trastuzumab emtansine and margetuximab have no patient guide; their symptom advice is addressed to the prescriber. The patient-facing wording comes from the EU package leaflets and the US Medication Guides for trastuzumab deruxtecan and zanidatamab. The lapatinib texts ask patients to tell their doctor about heart symptoms but give no urgency for them."]},"route":"/protocols/left-ventricular-dysfunction-on-her2-targeted-drugs/","neighbours":{"technology":[{"id":"cardio-oncology","kind":"technology","name":"Cardio-oncology","route":"/technologies/cardio-oncology/"}],"protocol":[{"id":"cardio-oncology-risk-assessment-and-cardiac-surveillance","kind":"protocol","name":"Heart risk assessment and monitoring before, during and after heart-toxic cancer treatment","route":"/protocols/cardio-oncology-risk-assessment-and-cardiac-surveillance/"},{"id":"cardiomyopathy-surveillance-after-childhood-cancer","kind":"protocol","name":"Heart scans after anthracyclines or chest radiotherapy for cancer in childhood, adolescence or young adulthood","route":"/protocols/cardiomyopathy-surveillance-after-childhood-cancer/"},{"id":"irae-myocarditis","kind":"protocol","name":"Immune-related myocarditis from checkpoint inhibitors","route":"/protocols/irae-myocarditis/"}],"section":[{"id":"supportive-care","kind":"section","name":"Supportive Care & Survivorship","route":"/fronts/supportive-care/"}],"drug":[{"id":"lapatinib","kind":"drug","name":"Lapatinib","route":"/drugs/lapatinib/"},{"id":"margetuximab","kind":"drug","name":"Margetuximab","route":"/drugs/margetuximab/"},{"id":"pertuzumab","kind":"drug","name":"Pertuzumab","route":"/drugs/pertuzumab/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"},{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/"},{"id":"zanidatamab","kind":"drug","name":"Zanidatamab","route":"/drugs/zanidatamab/"}],"institution":[{"id":"ema","kind":"institution","name":"European Medicines Agency","route":"/institutions/ema/"},{"id":"esmo","kind":"institution","name":"European Society for Medical Oncology (ESMO)","route":"/institutions/esmo/"}],"term":[{"id":"cardiotoxicity","kind":"term","name":"Cardiotoxicity (LVEF decline, cardiomyopathy)","route":"/terms/cardiotoxicity/"},{"id":"trastuzumab-cardiotoxicity","kind":"term","name":"Trastuzumab cardiotoxicity","route":"/terms/trastuzumab-cardiotoxicity/"}],"paper":[{"id":"paper-lyon-eur-heart-j","kind":"paper","name":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","route":"/key-papers/paper-lyon-eur-heart-j/"}]}}